Polymer Nanoparticles for the Delivery of Anticancer Drugs, 3rd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 571

Special Issue Editor


E-Mail Website
Guest Editor
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Interests: nano drug delivery systems; nucleic acid delivery; controlled release systems; targeted drug delivery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanotechnology is at the commanding height of strategic technology in the 21st century, among which nanoparticles are revolutionizing the field of drug delivery, especially regarding cancer; their therapeutic effects in practical applications, though still far from satisfactory on account of their poor water solubility and poor pharmacokinetics, are extremely beneficial. Luckily, the booming nanocarriers have introduced bright prospects for gaining encouraging therapeutic outcomes since they can be engineered to enhance the solubility and circulation time of drugs, as well as efficiently bringing drugs to cancer cells. Accordingly, promising polymer nanoparticles are being developed to deliver anticancer drugs, such as PEG-PLA polymer micelles, PLGA nanoparticles, liposomes, and gold nanoparticles. Advanced delivery systems have also been designed to deliver drugs specifically to the tumor site based on their stimuli-responsive properties and cancer cell-specific markers. Nevertheless, the further exploration of identifying targeted molecules and designing nanocarriers is still worth continuing. Therefore, we would like to invite you to contribute both reviews and original articles highlighting recent progress in the development of polymer nanoparticles for the delivery of anticancer drugs, which will be published as part of a Special Issue entitled “Polymer Nanoparticles for the Delivery of Anticancer Drugs.” Main topics include but are not limited to, polymer nanoparticles for chemotherapeutic drug delivery, nucleic acid delivery, chemotherapeutic drug and nucleic acid-based co-delivery, photosensitizer delivery, etc.

We look forward to receiving your contributions.

Prof. Dr. Wei Huang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted nanoparticles
  • anticancer drug delivery
  • siRNA delivery
  • co-delivery system
  • stimuli-responsive
  • polymer nanoparticles
  • controlled release systems
  • solubilization

Related Special Issues

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 12051 KiB  
Article
Synergistic Effects of Chemotherapy and Phototherapy on Ovarian Cancer Using Follicle-Stimulating Hormone Receptor-Mediated Liposomes Co-Loaded with SN38 and IR820
by Lina Pian, Bowen Zeng, Nuoya Wang, Shuangqing Wang, Hao Wu, Hongshuang Wan, Liqing Chen, Wei Huang, Zhonggao Gao, Dan Jin and Mingji Jin
Pharmaceutics 2024, 16(4), 490; https://doi.org/10.3390/pharmaceutics16040490 - 02 Apr 2024
Viewed by 435
Abstract
We have developed an ovarian cancer-targeted drug delivery system based on a follicle-stimulating hormone receptor (FSHR) peptide. The lipophilic chemotherapeutic drug SN38 and the photosensitizer IR820 were loaded into the phospholipid bilayer of liposomes. The combination of chemotherapy and phototherapy has become a [...] Read more.
We have developed an ovarian cancer-targeted drug delivery system based on a follicle-stimulating hormone receptor (FSHR) peptide. The lipophilic chemotherapeutic drug SN38 and the photosensitizer IR820 were loaded into the phospholipid bilayer of liposomes. The combination of chemotherapy and phototherapy has become a promising strategy to improve the therapeutic effect of chemotherapy drugs on solid tumors. IR820 can be used for photodynamic therapy (PDT), effectively converting near-infrared light (NIR) into heat and producing reactive oxygen species (ROS), causing damage to intracellular components and leading to cell death. In addition, PDT generates heat in near-infrared, thereby enhancing the sensitivity of tumors to chemotherapy drugs. FSH liposomes loaded with SN38 and IR820 (SN38/IR820-Lipo@FSH) were prepared using thin-film hydration-sonication. FSH peptide binding was analyzed using 1H NMR spectrum and Maldi-Tof. The average size and zeta potential of SN38/IR820-Lipo@FSH were 105.1 ± 1.15 nm (PDI: 0.204 ± 0.03) and −27.8 ± 0.42 mV, respectively. The encapsulation efficiency of SN38 and IR820 in SN38/IR820-Lipo@FSH liposomes were 90.2% and 91.5%, respectively, and their release was slow in vitro. FSH significantly increased the uptake of liposomes, inhibited cell proliferation, and induced apoptosis in A2780 cells. Moreover, SN38/IR820-Lipo@FSH exhibited better tumor-targeting ability and anti-ovarian cancer activity in vivo when compared with non-targeted SN38/IR820-Lipo. The combination of chemotherapy and photodynamic treatment based on an FSH peptide-targeted delivery system may be an effective approach to treating ovarian cancer. Full article
Show Figures

Figure 1

Back to TopTop